Our Mission is to Triple Survival by 2030
Welcome to the
2024 PanKind Scientific Meeting
2024 PanKind Scientific Meeting
Location
Wesley Conference Centre
220 Pitt Street
Sydney NSW 2000
October 28, 2024, 8:30 AM - 5:30PM
VISIT THEIR WEBSITE
220 Pitt Street
Sydney NSW 2000
October 28, 2024, 8:30 AM - 5:30PM
VISIT THEIR WEBSITE
Meeting Update
Program outline below
Organising Committee
The program has been designed by a dedicated organising committee
Professor Claudine Bonder
UNIVERSITY OF SOUTH AUSTRALIA
Professor Phoebe Phillips
UNIVERSITY OF NEW SOUTH WALES
Professor Fred Hollande
THE UNIVERSITY OF MELBOURNE
Meeting Program
| Monday 28th October 2024 | |
| 8:30-9:00 | Arrival and Registration |
| 9:00-9:10 | Welcome and Introduction Prof Chris Baggoley AO |
| 9:10-9:45 | Plenary Session Dr Urszula Wasko - The Olive Laboratory, Columbia University, New York Tumor-selective activity of RAS-GTP inhibition in pancreatic cancer |
| 9:45-10:45 | Session 1: Pathways to Tomorrow: Translational Research Chair: Prof Frederic Hollande University of Melbourne Dr Jennifer Devlin, Peter MacCallum Cancer Centre, University of Melbourne Targeting Pol II transcription cycles: a therapeutic strategy for pancreatic cancer Dr Purva Trivedi- Olivia Newton-John Cancer Research Institute Targeting Myeloid Specific HCK to Remodel Tumour Microenvironment in Pancreatic Cancer Dr Michael Lee - Peter MacCallum Cancer Centre Targeting RNA Processing in PDAC with PRMT5 Inhibition |
| 10:45-11:15 | Morning Tea |
| 11:15-12:15 | Session 2: New Treatments and Targeted Therapies Chair: Prof Ross McKinnon - Flinders University Dr Brooke Pereira - Garvan Institute of Medical Research Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response A/ Prof Jennette Sakoff - Calvary Mater Hospital Targeting the Aryl Hydrocarbon Receptor Pathway Prof Eva Bezak- University of South Australia The promise of radioimmunotherapy for the treatment of pancreatic cancer |
| 12:15-13:00 | Panel Discussion Lost in Translation: The Real Barriers to Implementing Pancreatic Cancer Advances |
| 13:00-14:00 | Lunch Break |
| 14:00-15:00 | Session 3: Early Detection Chair: Prof Claudine Bonder, University of South Australia Dr Belinda Lee - Walter and Eliza Hall Institute Exploring blood-based proteomics for early detection of pancreatic cancer A/ Prof Andrew Metz - Jreissati Pancreatic Centre, Epworth Cancer screening in high-risk patients - the APRISE study Dr Will McGahan- University of QLD Fibroblast activation protein as a target for stage I PDAC and high-grade dysplasia |
| 15:00-15:30 | Afternoon Tea |
| 15:30-17:15 | Session 4: New Concepts Proposals Chair and Moderator: Prof Phoebe Phillips, University of NSW Proposal 1: Electrical stimulation of the sympathetic nervous system to treat pancreatic Cancer Emma Brunton, Monash University Proposal 2: Targeting desaturases to improve gemcitabine/nab-paclitaxel efficacy in pancreatic ductal adenocarcinoma Sarah Hancock, Victor Chang Cardiac Research Institute Proposal 3: Improving the detection of circulating tumour DNA in early-stage pancreatic adenocarcinoma by enhancing circulating tumour DNA shedding Jean Winter, Flinders University Proposal 4: The Difference in BRCA Mutations in Pancreatic Cancer Michael KC Lee, Peter MacCallum Cancer Centre, Collaborative Centre for Cancer Genomic Medicine Proposal 5: Screening for pancreatic cancer in people with new-onset diabetes (the PaCNOD Study) Rachel Neale, QIMR Berghofer Medical Research Institute |
| 17:25 | Closing Remarks and Discussion |
| 17:30-20:00 | Networking - White Rabbit - All attendees. |
New Concepts Session
This year we are introducing a new session on the program: Pancreatic Cancer New Concepts.
This segment of the meeting is designed to introduce and discuss fresh ideas, innovative strategies, or emerging trends related to pancreatic cancer. This will provide an opportunity for researchers to present new concepts, ideas and potential projects for feedback and discussion with the pancreatic cancer community.
This segment of the meeting is designed to introduce and discuss fresh ideas, innovative strategies, or emerging trends related to pancreatic cancer. This will provide an opportunity for researchers to present new concepts, ideas and potential projects for feedback and discussion with the pancreatic cancer community.
New Concepts Eligibility Criteria
- Defined as translational or clinical research
- Contribution to area of unmet need in Pancreatic Cancer
- Are NEW concepts which have not been previously funded in whole
- Are in a stage of planning or early development.
Process
- The deadline for EOI’s has closed
- Four concepts will be chosen for presentation during the New Concepts Session
- The successful proposals accepted for presentation will be notified in advance of the meeting
- An expert reviewer (member of judging panel) will provide live feedback and the leader of the new concept will have a chance to respond
- Following presentation delegates will then be invited to provide comments and the presenter will have an opportunity to respond.
- One concept will have the opportunity to be selected for a $50,000 financial contribution for further protocol development, scientific planning and gathering of pilot data. The awarded concept will receive recognition for its innovation and potential impact on pancreatic cancer research.
In October last year, we welcomed over 100 researchers from across Australia to Sydney to attend the 2023 PanKind Scientific Meeting, uniting the community to exchange ideas and discuss the future of Pancreatic Cancer in Australia.
If you need more information or you have any questions, please don’t hesitate to contact the team at PanKind The Australian Pancreatic Cancer Foundation via email: [email protected]
If you have not registered yet, please register via the button below:
